Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

The bioenergetic deficits observed in Amyotrophic Lateral Sclerosis result from the disruption of mitochondria-associated ER membranes. Here, the authors show that this disruption impairs the use ...

Introduction: T regulatory cells (Tregs) inversely correlate with disease progression in Amyotrophic Lateral Sclerosis (ALS) and fast-progressing ALS patients have been reported to exhibit ...

usa.net Background Different amyotrophic lateral sclerosis (ALS) phenotypes have been recognised ... Objective To define the epidemiology and outcome of ALS phenotypes in a population based setting.